Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer.

Chung, Suyoun

Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. [electronic resource] - Oncotarget Dec 2012 - 1629-40 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1949-2553

10.18632/oncotarget.790 doi


Administration, Oral
Animals
Antineoplastic Agents--administration & dosage
Cell Proliferation--drug effects
Dose-Response Relationship, Drug
Drug Design
Female
High-Throughput Screening Assays
Humans
Inhibitory Concentration 50
Injections, Intravenous
MCF-7 Cells
Male
Mice
Mice, Inbred BALB C
Mice, Inbred NOD
Mice, SCID
Microfilament Proteins--metabolism
Molecular Structure
Molecular Targeted Therapy
NIH 3T3 Cells
Naphthyridines--administration & dosage
Neoplasms--drug therapy
Phosphorylation
Proteasome Endopeptidase Complex--metabolism
Protein Kinase Inhibitors--administration & dosage
Protein Serine-Threonine Kinases--antagonists & inhibitors
RNA Interference
Small Molecule Libraries
Structure-Activity Relationship
Time Factors
Transfection
Tumor Burden--drug effects
Xenograft Model Antitumor Assays
src Homology Domains